Dual Color -Chromogenic in Situ Hybridization Approaches to Evaluate HER2/Neu Gene Amplification in Breast Carcinomas
Abstract
Shoroq Mohammed AL-Temimi and Adel Mosa AL-Rekabi
Breast cancer continue to be the most frequent malignant tumor in women, constituting the second most common fatal malignant tumor in women. The validated prognostic HER/2neu. Aim of the study:- Evaluating HER-2 by immunohistochemical (IHC) for protein expression and in situ hybridization (ISH) by dual-color chromogenic insitu hybridization (DC-CISH) technique for HER-2 gene copy amplification and chromosome 17/CEN (chr.17 CEN) aneuploidy in breast cancer.
Methods: This is a prospective study, where by fifty-pairs of fresh tissues from both breast cancer of invasive ductal carcinoma and apparently normal adjacent tissues (NATs) which considered as healthy normal internal control. we select only positive cases of HER-2 /neu by IHC (16 cases which included score+2 and score +3 HER-2 by IHC) for gene amplification by DC-CISH were done in CPHL/Baghdad.
Results: Out of 6 cases with her2(score +2) in breast cancer by IHC expression, 2 (33.33%) show no amplification, while all cases4(66.67%), show low amplification. All cases with (score +3) by IHC, showed gene amplification. Out of 10 cases with (score +3) by IHC, 2 cases (20%) showed low amplification while majority of cases,8 (80%) showed high amplification.
Conclusion: The DC-CISH is confirmatory technique for the detection of both HER-2 gene amplification and multiplication of chromosome 17/CEN in breast cancer.
How to Cite this Article |
Pubmed Style Shoroq Mohammed AL-Temimi and Adel Mosa AL-Rekabi. Dual Color -Chromogenic in Situ Hybridization Approaches to Evaluate HER2/Neu Gene Amplification in Breast Carcinomas. SRP. 2020; 11(10): 114-119. doi:10.31838/srp.2020.10.19 Web Style Shoroq Mohammed AL-Temimi and Adel Mosa AL-Rekabi. Dual Color -Chromogenic in Situ Hybridization Approaches to Evaluate HER2/Neu Gene Amplification in Breast Carcinomas. http://www.sysrevpharm.org/?mno=10257 [Access: March 29, 2021]. doi:10.31838/srp.2020.10.19 AMA (American Medical Association) Style Shoroq Mohammed AL-Temimi and Adel Mosa AL-Rekabi. Dual Color -Chromogenic in Situ Hybridization Approaches to Evaluate HER2/Neu Gene Amplification in Breast Carcinomas. SRP. 2020; 11(10): 114-119. doi:10.31838/srp.2020.10.19 Vancouver/ICMJE Style Shoroq Mohammed AL-Temimi and Adel Mosa AL-Rekabi. Dual Color -Chromogenic in Situ Hybridization Approaches to Evaluate HER2/Neu Gene Amplification in Breast Carcinomas. SRP. (2020), [cited March 29, 2021]; 11(10): 114-119. doi:10.31838/srp.2020.10.19 Harvard Style Shoroq Mohammed AL-Temimi and Adel Mosa AL-Rekabi (2020) Dual Color -Chromogenic in Situ Hybridization Approaches to Evaluate HER2/Neu Gene Amplification in Breast Carcinomas. SRP, 11 (10), 114-119. doi:10.31838/srp.2020.10.19 Turabian Style Shoroq Mohammed AL-Temimi and Adel Mosa AL-Rekabi. 2020. Dual Color -Chromogenic in Situ Hybridization Approaches to Evaluate HER2/Neu Gene Amplification in Breast Carcinomas. Systematic Reviews in Pharmacy, 11 (10), 114-119. doi:10.31838/srp.2020.10.19 Chicago Style Shoroq Mohammed AL-Temimi and Adel Mosa AL-Rekabi. "Dual Color -Chromogenic in Situ Hybridization Approaches to Evaluate HER2/Neu Gene Amplification in Breast Carcinomas." Systematic Reviews in Pharmacy 11 (2020), 114-119. doi:10.31838/srp.2020.10.19 MLA (The Modern Language Association) Style Shoroq Mohammed AL-Temimi and Adel Mosa AL-Rekabi. "Dual Color -Chromogenic in Situ Hybridization Approaches to Evaluate HER2/Neu Gene Amplification in Breast Carcinomas." Systematic Reviews in Pharmacy 11.10 (2020), 114-119. Print. doi:10.31838/srp.2020.10.19 APA (American Psychological Association) Style Shoroq Mohammed AL-Temimi and Adel Mosa AL-Rekabi (2020) Dual Color -Chromogenic in Situ Hybridization Approaches to Evaluate HER2/Neu Gene Amplification in Breast Carcinomas. Systematic Reviews in Pharmacy, 11 (10), 114-119. doi:10.31838/srp.2020.10.19 |